NEW YORK, Dec. 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Heat Biologics, Inc. ("Heat Biologics" or the "Company") (NASDAQ: HTBX). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/htbx.
The investigation concerns whether Heat Biologics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On November 30, 2016, after the market closed, Heat Biologics revealed information from its Phase II trial assessing HS-410 and announced that patients "responses did not translate into clinical outcomes, and there was no statistically significant difference in the primary endpoint (proportion of recurrence-free survival at one year) between the vaccine and placebo arms of the trial." Following this news, Heat Biologics stock dropped during intraday trading on December 1, 2016. If you are aware of any facts relating to this investigation, or purchased Heat Biologics shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/htbx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.